MedWatch

Danish biotech company granted millions to develop custom-made cancer vaccine

Innovation Fund Denmark has granted a small Danish biotech company millions to develop a cancer vaccine targeting the unique cell changes in the individual patient. If the company succeeds, it will enter a billion-dollar market.

Foto: Evaxion, PR

The Danish biotech company Evaxion has received approximately DKK 6 million (around USD 956,700) from Innovation Fund Denmark’s DKK 30.8 million-budget. The money is to finance the development of a therapeutic cancer vaccine for making the immune system recognize unique changes in the individual patient’s cancer cells.

By means of gene technology and artificial intelligence, the new immunotherapy will be customized the individual patient and eliminate the cancer cells more effectively and without the side-effects of existing therapies.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier